- Trial phase
- Phase 3
- Time to market
- Pivotal data from the PiNACLE trial is expected mid-2027, with a BLA submission planned for the second half of 2027. If approved, commercial launch would likely follow in 2028.
- Why 7/10
- The next hard, dated catalyst is the ASH 2026 Annual Meeting (December 12-15, 2026), where updated data from the PiNACLE pivotal trial and Phase 1/2 second-line cohort will be presented. Ronde-cel is Lyell's lead and essentially only late-stage asset, making this a high-concentration event. The proximity (~5 weeks) and the drug's centrality to the company's valuation justify a 7, though the catalyst is a conference data presentation rather than a regulatory binary decision.
The next major catalyst is the ASH 2026 Annual Meeting (December 12-15, 2026), where updated data from the PiNACLE pivotal trial (3L+) and the Phase 1/2 second-line cohort will be presented in oral and poster sessions. Strong data could drive the stock toward analyst targets (mean $37.88), while disappointing durability or safety signals would pressure shares. The pivotal data readout expected in mid-2027 and BLA submission in H2 2027 are the longer-term binary events.
Price Chart
Executive Summary
Ronde-cel (rondecabtagene autoleucel) is Lyell Immunopharma's next-generation, dual-targeting CD19/CD20 CAR T-cell therapy for relapsed/refractory large B-cell lymphoma (LBCL). In the ongoing PiNACLE pivotal trial (3L+ setting), ronde-cel showed a 91% overall response rate and 77% complete response rate among 44 evaluable patients, with no Grade 3 or higher cytokine release syndrome (CRS) and low rates of severe neurotoxicity. The company raised $80 million in November 2026 to fund the program toward a planned BLA submission in the second half of 2027. Updated data from more than 80 patients will be presented at the ASH 2026 Annual Meeting (December 12-15, 2026).
How It Works
Ronde-cel is a personalized cell therapy (CAR T-cell) made from a patient's own immune cells. The cells are genetically engineered to carry two targeting molecules (CD19 and CD20) that recognize and attack cancerous B cells in lymphoma. It is designed to improve durability of response by enriching for stem-like T cells (CD62L+) and to reduce severe side effects compared to existing single-target CAR T therapies.
Trial Status
Two pivotal trials are underway: PiNACLE (single-arm, 3L+ LBCL) and PiNACLE-H2H (randomized Phase 3 head-to-head vs approved CD19 CAR T therapies in 2L LBCL). As of the Q3 2026 data cutoff, 44 patients were efficacy-evaluable in the 3L+ PiNACLE trial, showing 91% ORR and 77% CR. The 2L cohort showed a 95% ORR. Safety data across more than 100 patients showed no Grade >=3 CRS and low rates of severe ICANS, supporting potential outpatient administration. Manufacturing success rate is 97%.
The Two-Sided Case
Upcoming Catalysts
- ASH 2026 Annual Meeting (December 12-15, 2026): Oral and poster presentations of updated ronde-cel data from PiNACLE pivotal trial (3L+) and Phase 1/2 2L cohort in more than 80 patients.
- PiNACLE pivotal data readout (mid-2027): The primary efficacy analysis expected to support BLA submission.
- BLA submission to FDA (H2 2027): Planned regulatory filing for ronde-cel in 3L+ R/R LBCL.
- PiNACLE-H2H Phase 3 head-to-head trial: Ongoing randomized trial vs Yescarta/Breyanzi in 2L LBCL; future readout.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Lyell Immunopharma, Inc Press Release LYEL ·Originating report